Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (81-90 of 208) with videos related to

Pageof 21
Sort By:
Blood|November 15, 2014
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2Yuan Xiao Zhu, Hongwei Yin, Laura A Bruins, et al.
Ejhaem|May 12, 2025
A Single-Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q AbnormalitiesAshish Patel, Esther Masih-Khan, Adam Smith, et al.
European Journal of Haematology|January 15, 2026
Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal ImpairmentRintu Sharma, Eshetu G Atenafu, Esther Masih-Khan, et al.
Blood|August 30, 2002
A molecular compendium of genes expressed in multiple myelomaJaime O Claudio, Esther Masih-Khan, Hongchang Tang, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 9, 2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaSundar Jagannath, Ravi Vij, A Keith Stewart, et al.
The Journal of Clinical Investigation|April 24, 2008
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activityRodger E Tiedemann, Xinliang Mao, Chang-Xin Shi, et al.
Blood Cancer Journal|February 12, 2019
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4Yuan Xiao Zhu, Chang-Xin Shi, Laura A Bruins, et al.
British Journal of Haematology|February 17, 2015
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaJoseph R Mikhael, Craig B Reeder, Edward N Libby, et al.
Cancer Gene Therapy|September 23, 2003
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancerSuzane Trudel, John Trachtenberg, Ants Toi, et al.
Cancer Research|May 6, 2004
Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivoYoung Trieu, Xiao-Yan Wen, Brian F Skinnider, et al.
Pageof 21

Showing results (81-90 of 208) with videos related to

Sort By:
Pageof 21
Blood|November 15, 2014
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2Yuan Xiao Zhu, Hongwei Yin, Laura A Bruins, et al.
Ejhaem|May 12, 2025
A Single-Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q AbnormalitiesAshish Patel, Esther Masih-Khan, Adam Smith, et al.
European Journal of Haematology|January 15, 2026
Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal ImpairmentRintu Sharma, Eshetu G Atenafu, Esther Masih-Khan, et al.
Blood|August 30, 2002
A molecular compendium of genes expressed in multiple myelomaJaime O Claudio, Esther Masih-Khan, Hongchang Tang, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 9, 2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaSundar Jagannath, Ravi Vij, A Keith Stewart, et al.
The Journal of Clinical Investigation|April 24, 2008
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activityRodger E Tiedemann, Xinliang Mao, Chang-Xin Shi, et al.
Blood Cancer Journal|February 12, 2019
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4Yuan Xiao Zhu, Chang-Xin Shi, Laura A Bruins, et al.
British Journal of Haematology|February 17, 2015
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaJoseph R Mikhael, Craig B Reeder, Edward N Libby, et al.
Cancer Gene Therapy|September 23, 2003
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancerSuzane Trudel, John Trachtenberg, Ants Toi, et al.
Cancer Research|May 6, 2004
Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivoYoung Trieu, Xiao-Yan Wen, Brian F Skinnider, et al.
Pageof 21